drugset / Trial / NCT00170677

Topotecan Weekly Versus Topotecan Day 1-5 in Patient With Platin-resistant Ovarian Cancer

NCT00170677

Non-randomizedParallel-groupOpen-labelTreatment

Summary

Comparison of topotecan weekly vs. topotecan day 1-5. The compatibility and activity are to be examined.

Timeline

Start
2005-09
Primary completion
2013-01
Completion
2013-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Topotecan Small molecule 1.25 mg/m2 Intravenous
Comparator Topotecan Small molecule 4 mg/m2 Intravenous

Indications